Intrinsiqq
HUTCHMED (China) Ltd logo

HUTCHMED (China) Ltd Financials

HCM

⊜ Compare

All currency values in $ millions unless otherwise noted

Scroll

Showing 5 of 12 available years
Income Statement
DEC 2025
DEC 2024
DEC 2023
DEC 2022
DEC 2021
Revenues
Revenue$549$630$838$426$356
Cost of Revenue$336$349$384$311$296
Gross Profit$212$281$454$115$60
Operating Expenses
Selling & Marketing$36$49$53$44$38
General & Administrative$67$64$80$92$89
Research & Development$148$212$302$387$299
Provision for Doubtful Accounts$0$0$0$0$0
Total Operating Expenses$588$674$820$834$684
Operating Income-$39-$44$18-$408-$328
Non-Operating
Net Interest Expense$47$37$35$9$1
Other Non-Operating Income (Expense)$491$5$5-$12$111
EBT (Earnings Before Tax)$499-$1$58-$410-$216
Income Tax Expense$64$7$5-$0$12
Minority Interest$1$0$0$0$28
Net Income
Net Income$457$38$101-$361-$195
Per Share Data
Revenue Per Share$0.63$0.72$0.96$0.50$0.45
EPS (Basic)$0.53$0.04$0.12-$0.43-$0.25
EPS (Diluted)$0.52$0.04$0.12-$0.43-$0.25
Weighted Avg Shares (Basic)858.3M855.4M849.7M847.1M792.7M
Weighted Avg Shares (Diluted)872.9M872.8M869.2M847.1M792.7M
Shares Outstanding872.9M872.8M869.2M847.1M792.7M

HUTCHMED (China) (HCM) financials: revenue, profit and margins

HUTCHMED (China) (HCM) generated about $549 million in revenue and $457 million in net income (a 83.3% net margin) over the trailing twelve months, growing at roughly 19.2% a year. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

What is HUTCHMED (China)'s (HCM) revenue?+

HUTCHMED (China) generated about $549 million in revenue over the trailing twelve months. Revenue has grown at roughly 19.2% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.

Is HUTCHMED (China) profitable?+

Yes, HUTCHMED (China) reported about $457 million in net income over the trailing twelve months, a net profit margin of roughly 83.3%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

What are HUTCHMED (China)'s profit margins?+

HUTCHMED (China) runs a gross margin of about 38.7%, an operating margin of about -7.1%, a net margin of about 83.3%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.

How fast is HUTCHMED (China) growing?+

HUTCHMED (China)'s revenue has compounded at roughly 19.2% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside HCM's margins and free cash flow. This is analysis from SEC filings, not investment advice.

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-K filed 5 Mar 2026, covering the period ending 31 Dec 2025, as reported to the SEC. Data last refreshed 7 Jun 2026. How this is calculated.

Peers

Pharmaceutical Preparations · Pick stocks to compare with HCM

CompareIntrinsic value
TVTXTravere Therapeutics Inc.
$52.64+6.54%52
MIRMMirum Pharmaceuticals Inc.
$95.00+9.16%30
BBIOBridgeBio Pharma, Inc.
$77.89+5.21%30
ORGOOrganogenesis Holdings Inc.
$0.87+4.19%50
CPRXCatalyst Pharmaceuticals Inc.
No recent price73
OPKOpko Health Inc.
$1.77+2.91%25
NATRNature's Sunshine Products Inc.
$12.84+6.38%70
ARWRArrowhead Pharmaceuticals Inc.
$61.65+3.56%40

Held by ETFs

HCM is in 1 US ETF. The largest of them, with HCM's weight in each:

Spot a number that looks wrong? Check it in HCM's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing HCM

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.